Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye

What is it about?

Only 50% of patients with symptoms of dry eye have clinically significant ocular surface inflammation. Testing for elevated MMP-9 with the InflammaDry test confirms the presence or absence of ocular surface inflammation. If inflammation is present anti-inflammatory therapies are beneficial and punctal occlusion should be avoided.

Featured Image

Why is it important?

This retrospective study shows that InflammaDry testing can identify patients with elevated MMP-9 (ocular surface inflammation) that are more likely to benefit from expensive, chronic anti-inflammatory therapy. Enriching the patient population enhances the therapeutic efficacy of dry eye medications. In addition, preoperative treatment of dry eye improves preoperative surgical measurements and post operative outcomes.